OncoMatch/Clinical Trials/NCT07366528
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Is NCT07366528 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Oxaliplatin plus S-1 and Docetaxel plus S-1 for gastric cancer (gc).
Treatment: Oxaliplatin plus S-1 · Docetaxel plus S-1 — This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage IIIA (T2N3A, T3N2, T4AN1, T4AN2, T4BN0), IIIB (T1N3B, T2N3B, T3N3A, T4AN3A, T4BN1, T4BN2), IIIC (T3N3B, T4AN3B, T4BN3A, T4BN3B) (AJCC)
American Joint Committee on Cancer stage IIIA (T2N3a, T3N2, T4aN1, T4aN2, T4bN0), IIIB (T1N3b, T2N3b, T3N3a, T4aN3a, T4bN1, T4bN2), IIIC (T3N3b, T4aN3b, T4bN3a, T4bN3b)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgery — adjuvant
patients underwent standard D2 gastrectomy and achieved R0 resection
Cannot have received: systemic therapy
had no systemic therapy like neoadjuvant therapy
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1.5x109/l, white blood count ≥3.5x109/l, platelets ≥75x109/l, hemoglobin (hb) ≥80g/l
Kidney function
serum creatinine ≤1.5x uln
Liver function
alt/ast ≤2.5x uln (for patient with liver metastasis alt/ast ≤5x uln), serum bilirubin ≤1.5x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify